Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Gilead Sciences, Inc. - Key Company Facts 8
Gilead Sciences, Inc. - Company Description 9
Gilead Sciences, Inc. - Top Executives 10
Gilead Sciences, Inc.- Top Executives Biographies 11
Gilead Sciences, Inc.- Head Office & Locations 13
Head Office - Country 13
Key Subsidiaries 14
Key Joint Ventures 15
Gilead Sciences, Inc. - Products and Services 16
Products 16
Gilead Sciences, Inc. - Historic Events 17
Gilead Sciences, Inc. - Company’s Management Discussion 18
Gilead Sciences, Inc. - Company’s Mission and Vision 23
Mission 23
Vision 23
Gilead Sciences, Inc. - Corporate Strategy 24
Gilead Sciences, Inc. - Business Description 27
Research and Development (R&D) Operations 27
Gilead Sciences, Inc. - ESG Spotlight 29
Environment 29
Social 30
Corporate Governance 30
Gilead Sciences, Inc. - SWOT Analysis 32
Overview 32
Strengths 34
Weaknesses 38
Opportunities 40
Threats 42
Gilead Sciences, Inc. - PESTLE Analysis 44
Overview 44
Political Factors 46
Economic Factors 48
Social Factors 50
Technological Factors 52
Legal Factors 53
Environmental Factors 55
Gilead Sciences, Inc. - Financial Deep Dive 56
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 56
Profit and Loss Statement 58
Summary of Profit and Loss Statement 58
Key Financial Ratio Analysis 60
Gilead Sciences, Inc. - Ratio Charts 61
Activity Ratio Charts 61
Growth Ratios Charts 62
Leverage Ratio Charts 63
Liquidity Ratio Charts 63
Profitability Ratio Charts 65
Competing Players 66
Snapshot of Competing Players 67
AbbVie Inc 67
Key Company Facts 67
Company Description 67
Snapshot of Competing Players 69
Amgen, Inc. 69
Key Company Facts 69
Company Description 69
Snapshot of Competing Players 71
Bristol-Myers Squibb Company 71
Key Company Facts 71
Company Description 71
Snapshot of Competing Players 73
GSK plc 73
Key Company Facts 73
Company Description 73
Snapshot of Competing Players 75
Pfizer Inc. 75
Key Company Facts 75
Company Description 75
Gilead Sciences, Inc. - In the News 78
12-Sep-2024- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada? in Second Pivotal Phase 3 Trial 78
10-Sep-2024- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies 81
05-Sep-2024- Gilead to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer 82
14-Aug-2024- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA 84
08-Aug-2024- Gilead Sciences Announces Second Quarter 2024 Financial Results 87
Gilead Sciences, Inc.- Key Deals 90
22-Feb-2023 - Kite Completes Acquisition of Tmunity 90

30-Jan-2023 - Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma 91
27-Dec-2022 - Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics 92
07-Dec-2022 - Kite and Daiichi Sankyo Announce Changes to YESCARTA? CAR T-Cell Therapy Licensing Agreement in Japan 93
20-Oct-2022 - Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers 94
20-Sep-2022 - Gilead Sciences Completes Acquisition of MiroBio 95
15-Aug-2022 - Gilead to Acquire Remaining Worldwide Rights of Trodelvy 95
19-Jul-2022 - Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury? (Remdesivir) 97
Appendix 98
Definitions 98
SWOT Analysis 98
PESTLE Analysis 98
Value Chain Analysis 98
ESG Spotlight 98
Financial Deep Dive 98
Financial Ratios - 99
Activity Ratios 99
Growth Ratios 100
Leverage Ratios 101
Liquidity Ratios 102
Market Ratios 103
Profitability Ratios 103
Research Methodology 104
Disclaimer 105
Contact Us 105



List of Figures

Charts
Figure 1: Gilead Sciences, Inc.- SWOT Analysis 33
Figure 2: Gilead Sciences, Inc. - PESTLE Analysis 45
Figure 3: Gilead Sciences, Inc. - Average Share Price Trend - Oct-2023 to Oct-2024 57
Figure 4: Gilead Sciences, Inc. - Profit and Loss Statement - 2020-2023 59
Figure 5: Gilead Sciences, Inc. - Activity Ratio Charts 61
Figure 6: Gilead Sciences, Inc. - Growth Ratio Charts (Value %) 62
Figure 7: Gilead Sciences, Inc. - Leverage Ratio Charts 63
Figure 8: Gilead Sciences, Inc. - Liquidity Ratio Charts 64
Figure 9: Gilead Sciences, Inc. - Profitability Ratio Charts (Value %) 65
Figure 10: Competing Players - AbbVie Inc - Key Financials 68
Figure 11: Competing Players - Amgen, Inc. - Key Financials 70
Figure 12: Competing Players - Bristol-Myers Squibb Company - Key Financials 72
Figure 13: Competing Players - GSK plc - Key Financials 74
Figure 14: Competing Players - Pfizer Inc. - Key Financials 76

List of Tables

Tables
Table 1: Gilead Sciences, Inc. - Company Facts
Table 2: Gilead Sciences, Inc. - Top Executives
Table 3: Gilead Sciences, Inc. - Top Executives Biographies
Table 4: Gilead Sciences, Inc. - Subsidiaries
Table 5: Gilead Sciences, Inc. - Key Joint Ventures
Table 6: Gilead Sciences, Inc. - Products
Table 7: Gilead Sciences, Inc. - Historic Events
Table 8: Gilead Sciences, Inc. - Share Price Trend - Oct-2023 to Oct-2024
Table 9: Gilead Sciences, Inc.- Ratio Analysis - 2019-2022
Table 10: Gilead Sciences, Inc. -Competing Players